Site‑Specific Antibodies Drive Targeted Protein Degradation
1. Literature Information
This literature dissects innovative research on site‑specific antibody‑mediated targeted protein degradation, focusing on lysosome‑directed elimination of extracellular and membrane proteins via hepatocyte asialoglycoprotein receptor (ASGPR) and homogeneous antibody–ligand conjugation.
2. Research Background
Conventional drug development mainly inhibits enzymatic activity or blocks protein–protein interactions. For disease‑related non‑enzymatic secreted and membrane proteins, such strategies show limited efficacy and drug resistance. Targeted protein degradation uses cellular ubiquitin–proteasome and lysosomal pathways to remove pathogenic proteins fundamentally. ASGPR, highly and specifically expressed on hepatocytes with efficient endocytosis, is an ideal target for liver‑directed degradation. However, stable and homogeneous antibody–ligand conjugation remains a technical bottleneck.
3. Research Approach
The study established a site‑specific antibody–ligand conjugation platform based on chemoenzymatic Fc glycan remodeling:
Enzymatically cleave native Fc N‑glycans to expose specific glycosylation sites.
Install unnatural glycans with reactive groups via glycosyltransferases.
Covalently link ASGPR high‑affinity ligands through click chemistry.
This method ensures uniform ligand modification at defined positions, avoiding heterogeneity and activity loss from random conjugation.
4. Research Outcomes
Ligand structure determines receptor binding and endocytosis efficiency. Synthetic triantennary N‑acetylgalactosamine clusters cause a hook effect at high concentrations, reducing degradation.
Natural triantennary complex N‑glycans mediate robust, dose‑dependent degradation without hook effect.
Anti‑PCSK9 antibody–glycan ligand complexes trigger ASGPR‑mediated endocytosis and lysosomal degradation, significantly improving extracellular PCSK9 clearance over unmodified antibodies.
This platform achieves true degradation rather than simple blocking, providing a new mechanism for extracellular target elimination.
[Image Location: Schematic of PCSK9–LDLR–ASGPR complex formation, endocytosis and lysosomal degradation pathway]
5. Product Empowerment
ANT BIO PTE. LTD. provides high‑performance site‑specific antibodies to support targeted protein degradation research.
Histone H3 (acetyl K14) Recombinant Rabbit mAb (S‑R398, Cat. No.: S0B0755)
Exceptional site and modification specificity, no cross‑reaction with unmodified H3 or other acetylation sites.
High affinity and sensitivity ideal for ChIP, CUT&Tag and epigenomic analysis.
Excellent batch consistency and stability for large‑scale and long‑term studies.
Broad species reactivity covering human, mouse, rat and other model organisms.
6. Brand Mission
ANT BIO PTE. LTD. is a premier life science reagent supplier focusing on antibodies, proteins, kits and general reagents. We own three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies) and UA (recombinant proteins). We dedicate to delivering high‑quality, reliable tools to accelerate life science research, disease mechanism study and therapeutic innovation.
7. Related Product List
Product Name Catalog No. Type Core Application
Histone H3 (acetyl K14) Recombinant Rabbit mAb S0B0755 Recombinant Rabbit mAb Epigenetics, chromatin dynamics, ChIP, CUT&Tag
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights
